07:49 AM EST, 11/12/2025 (MT Newswires) -- Zenas BioPharma ( ZBIO ) reported a Q3 net loss Wednesday of $1.22 per diluted share, narrower than a loss of $5.02 a year earlier.

Three analysts surveyed by FactSet expected a loss of $0.83.

As of Sept. 30, the company said it had $301.6 million in cash, cash equivalents, and investments, which along with $120 million raised from a private placement in October is expected to fund operations and capital expenditures through Q4 of 2026.